Life sciences dealmaker and IP licensing lawyer Adam Golden is leaving Hogan Lovells to join Freshfields Bruckhaus Deringer, a firm that has made a slew of flashy hires in the U.S. over the past 18 months.
Golden will head Freshfields’ U.S. life sciences practice after representing clients such as Novartis AG, Gilead Sciences Inc., and Celgene Corp. He handles license and collaboration deals, M&A, financings, and commercial transactions.
“The firm has really made significant strides in the U.S.,” Golden said of Freshfields. “I see what’s happening and the types of transactions, antitrust matters, litigation and other matters the firm is working on, and it has clearly gotten my attention.”
Freshfields first turned heads in the U.S. with the 2019 hire of former Cleary, Gottlieb & Steen dealmaker Ethan Klingsberg. It has since hired partners from firms including Kirkland & Ellis, Latham & Watkins, Davis Polk, Wilson Sonsini, Willkie Farr & Gallagher.
Last year, Freshfields opened in Silicon Valley with a group move that included recruiting John Fisher from Sidley Austin. Fisher now leads the firm’s U.S. technology and life sciences M&A practice.
Golden’s move keeps alive a hot market for life sciences lawyers in 2021. It comes just a few months after Hogan Lovells partner Asher Rubin, who co-led Hogan Lovells’ life sciences practice, departed for Sidley Austin.
Golden served as head of Hogan Lovells’ New York corporate practice. He worked across the table from Freshfields lawyers on a complex asset swap completed in 2015 between pharmaceutical giants Novartis and GlaxoSmithKline plc.
Jennifer Bethlehem, the London-based head of Freshfields’ healthcare practice, said the firm’s strategy to grow its life sciences business preceded the pandemic. The pharmaceutical industry’s role in the pandemic, along with innovations such as new types of drugs and therapies, has made life sciences even more important.
“I always used to say Adam Golden is my favorite partner that’s not a partner of mine,” Bethlehem said in an interview. “As I’ve been working with the firm to develop our life sciences strategy over many years now, in my mind Adam has always been a part of that strategy.”